Pulse Biosciences Announces Late Breaking Oral Presentation of Sebaceous Hyperplasia Study Results at the 2019 AAD Annual Meeting

gbaf1news

Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX„¢ System, today announced that clinical results from its recently completed Sebaceous Hyperplasia study will be presented at the American Academy of Dermatology (AAD) Annual Meeting being held March 1-5, 2019, in Washington D.C. Girish Munavalli, M.D., M.H.S., F.A.C.M.S, of Dermatology, Laser & Vein Specialists of the Carolinas, will present the data at the Late-Breaking Research; Procedural Dermatology Scientific Session. The AAD Annual Meeting is one of the largest scientific meetings of dermatologists featuring the latest information on skin, hair and nails, presented by world-renowned experts in the field of dermatology.

The details of the presentation are as follows:

Title: Safety and Efficacy of Nano-Pulse Stimulation in the Treatment of Patients with Sebaceous Hyperplasia Date and Time: Saturday March 2, 2019 at 9:50 a.m.ET Session: Late-Breaking Research: Procedural Dermatology (9:00 a.m. “ 11:00 a.m.ET) Location: Walter E. Washington Convention Center, Salon H

About Nano-Pulse Stimulation

Pulse Biosciences patented Nano-Pulse Stimulation„¢ technology (NPS„¢), delivered by its proprietary, tunable CellFX System, is characterized by the delivery of a series of nanosecond duration electrical energy pulses, with pulse durations from billionths up to a millionth of a second. This unique non-thermal technology targets cellular structures while sparing non-cellular structures, making it uniquely well-suited for cellular targets in the dermis, such as sebaceous glands and other adnexal structures.

About Pulse Biosciences

Pulse Biosciences is a novel medical therapy company bringing to market its proprietary CellFX„¢ System. The Companys novel CellFX System provides a precise, non-thermal delivery of nanosecond duration energy pulses that impact cells in treated tissue while sparing non-cellular tissue. This unique mechanism of action disrupts the functions of internal cell structures while maintaining the outer cell membrane, initiating a cascade of events within the cell that results in regulated cell death. The novel characteristics of the Companys CellFX System has the potential to significantly benefit patients across multiple medical applications, including dermatology, the Companys first planned commercial application. In pre-clinical studies, NPS has demonstrated an ability to induce immunogenic cell death in several cancer cell lines. The Company believes its NPS platform technology may play a role in immuno-oncology as a focal tumor treatment that can initiate an adaptive immune response. More information can be found at www.pulsebiosciences.com.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to or implying Pulse Biosciences expectations regarding the presentation of clinical data, commercialization of the CellFX System, regulatory clearance and the timing of FDA filings or approvals for products and indications, matters related to its pipeline of product candidates, future financial performance and business strategies and other future events. These statements are not historical facts but rather are based on Pulse Biosciences current expectations, estimates, and projections regarding Pulse Biosciences business, operations and other similar or related factors. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

CAUTION: Pulse Biosciences CellFX System and Nano-Pulse Stimulation (NPS) are for investigational use only.

Investors:
Brian Dow
Sr. Vice President and Chief
Financial Officer
[email protected]

Gitanjali Jain Ogawa
Solebury Trout
[email protected]
646-378-2949

Media:
Tosk Communications
Nadine D. Tosk, 504-453-8344
[email protected]